Sarcoidosis
Conditions
Interventions
Corticosteroid-treated group :prednisolone
Placebo:Placebo
Sponsors
The First Affiliated Hospital, Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 76 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were: (1) sarcoidosis confirmed by pathological results of lung tissues; (2) no significant cough, shortness of breath, and other symptoms presenting within the last month; (3) normal lung functions including FEV1, FEV1/FVC, FVC and diffusing capacity; (4) no disease involvement of external organs (including heart) other than chest.
Exclusion criteria
Exclusion criteria: (1) pulmonary tuberculosis, lymphoma or other pulmonary diseases; (2) inhaled or oral corticosteroid treatment within the last three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| newly developed clinical symptom;Lung functions (Including FEV1, FVC and DLCO);the yield of non-caseating granuloma in bronchial mucosa;CD4/CD8 ratio in bronchoalveolar lavage (BAL) fluid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events; | — |
Contacts
Public ContactLinling Cheng
Outcome results
None listed